The role of interferon-a (IFN-a) remains unclear in prevention of virus-induced hepatocellular carcinoma in humans. We have investigated it herewith in the X/myc transgenic mouse model of Hepadnavirus-related hepatocarcinogenesis because of upregulation of c-myc oncogene in the liver. We have demonstrated that IFN-a can downregulate dose-dependently hepatocyte proliferation and c-myc overexpression at early premalignant stages, while it does not affect either hepatocyte apoptosis or telomerase activity at these steps. However, continuous and long-term administration of IFN-a dose-dependently delays tumor onset in dysplastic livers and increases overall survival of animals, more efficiently whether started before the onset of dysplasia. The present study therefore highlights that early preventive administration of IFN-a can slow down evolution towards hepatocellular carcinoma via repression of c-myc and hepatocyte proliferation at premalignant steps in experimental cmyc-induced hepatocarcinogenesis. However, the transient effect observed in this study emphasizes a need to clarify the possible mechanisms of acquired resistance and subsequent therapeutic escape. Our experimental model may be a pertinent tool to explore antioncogenic properties of IFN-a in human cirrhotic livers showing c-myc upregulation.
Introduction
Hepatocellular carcinoma (HCC) is one of the most frequent fatal malignancies worldwide, strongly associated with hepatitis B virus (HBV) or hepatitis C virus (HCV) chronic liver infection (Ikeda et al., 1993) . Unfortunately, HCC is of poor prognosis since most patients cannot benefit of radical therapies and de novo recurrence is common after HCC ablation (Kumada et al., 1997) . Thus, primary and secondary preventive strategies are of major importance.
The type 1 interferons (IFNs), the IFN-a and IFN-b families, have diverse biological functions including antiviral activity, growth inhibition and immune cell stimulation. IFN-a was the first cytokine to be used clinically in human cancers. It is of note that although the benefit derived from IFN-a on established HCCs remains rather disappointing (Llovet et al., 2000) , several clinical studies have suggested that IFN-a might prevent HCC development in HBV-or HCV-related cirrhosis, although the data remain controversial and no clear mechanism has been described in these studies (Ikeda et al., 1998; Nishiguchi et al., 2001) .
Several experiments have described the direct antiproliferative and antioncogenic effect of IFNs on tumor cells (review in Wadler and Schwartz, 1990) . Clinical data on patients receiving IFN therapy have indicated a correlation between the in vitro sensitivity of malignant cells to the direct antiproliferative action of IFN and the in vivo clinical effects (Einhorn and Grander, 1996) . In ex vivo gene therapy models, stable expression of IFN-a in murine tumor cell lines has been shown to block their tumorigenic potential. Furthermore, IFN-b gene delivery by a replication-defective adenovirus has been shown to inhibit tumor formation and cause regression of established tumors in immune-deficient mice (Qin et al., 1998) . These studies underlying the possible direct nonimmune-mediated antitumoral effect of type 1 IFN were in accordance with its potent antiangiogenic and antitelomerase activities Xu et al., 2000) . Furthermore, the immune activation has appeared to play a role in the indirect impact of IFN-a on tumor inhibition because of infiltration of immunological effector cells (Ferrantini et al., 1994) . In summary, most of these studies have investigated the type 1 IFN's effects on cancerous cell growth, while no data have been forthcoming about its impact in vivo on the initiation of premalignant cells and the subsequent evolution toward cancer.
Experimental hepatocarcinogenesis greatly benefited over the last few years from the availability of transgenic mouse models, which provided new insights into the pathology of human HCC (Fausto, 1999) . The X/myc bitransgenic mouse model of HCC recapitulates different steps of hepatocarcinogenesis as it develops in Hepadnavirus-infected woodchucks as well as in human viral liver diseases (Liu et al., 1997; Terradillos et al., 1997; de La Coste et al., 1998) . X/myc mice have a deregulated and transient overexpression of the transgenic c-myc oncogene and HBV X factor in the liver during the first weeks of life. Early premalignant dysplastic hepatocytes appear, followed by a strong downregulation of c-myc and HBV X in tumor-free late dysplastic livers of adult mice. HCC lesions arise in late dysplastic livers in association with a marked upregulation of c-myc in tumors .
In a previous study, we had shown that early and prolonged administration of IFN-a could reduce the severity of dysplastic premalignant cells in the liver of the monotransgenic WHV/c-myc mouse model of virus-induced hepatocarcinogenesis. This effect was associated with a repression of deregulated c-myc overexpression and hepatocyte proliferation in premalignant stages (Merle et al., 2001) . Whether such an effect could inhibit HCC development and improve survival of mice has remained questionable, and we have used the X/myc bitransgenic mouse model in the present study to confirm it. Also, we have tested IFN-a impact on hepatocyte apoptosis and telomerase activity.
Results

Hepatocarcinogenesis in X/myc nontreated mice
Systematic killing at different ages and liver examination (Table 1) suggested that hepatocarcinogenesis was initiated in the first weeks of life, since 40% of nontreated mice had early dysplasia at 4 weeks and 100% at 12 weeks. HCC nodules appeared as early as 12 weeks and animals acquired subsequently large HCCs, became moribund and died of end-stage liver tumor within less than 36 weeks (median: 29 weeks) (Figure 1 ). Liver tumors, well differentiated and nonmetastatic HCC of the trabecular type (Figure 2 ), as well as hepatocyte dysplasia were indistinguishable from those previously described (Etiemble et al., 1994; Terradillos et al., 1997; Merle et al., 2001) . Consistent with the largely predominant C57B1/6 background of the lineage (Etiemble et al., 1994; Terradillos et al., 1997) , none of the nontransgenic age-matched females analysed in the present study developed any liver lesions (n ¼ 25).
IFN-a therapy dose-and time-dependently increased survival of X/myc mice via a delay of hepatocellular carcinoma onset
To assess the dose-dependent benefit of IFN-a therapy, high-dose (25 000 U/g per injection) was compared to low-dose (5000 U/g per injection) IFN-a therapy. Our data showed that high-dose IFN-a therapy started at birth significantly increased the survival of X/myc mice as compared to nontreated mice (median: 58 vs 29 weeks; log-rank test: Po0.0001), while low dose did not give any benefit (median: 28 vs 29 weeks; log-rank test: P ¼ 0.80) (Figure 1 ). However, IFN-a did not prevent HCC development since systematic killing and liver examination of the 8/16 (50%) high-dose-treated mice devoid of clinically palpable abdominal tumor at 60 weeks revealed that all of them had macroscopically identifiable small-sized HCC nodules confirmed by histological examination.
To assess whether prolonged life span was associated with a delay of microscopic HCC foci onset or a mere slowing down in progression of established large HCCs, additional high-dose-treated mice from birth were killed systematically at 40 weeks while all of them were free of externally palpable abdominal tumors. We showed that most of them had hepatocyte dysplasia without HCC, giving a significant improvement in tumor-free survival as compared to nontreated mice that died of end-stage liver tumor before 35 weeks of age (w 2 test with Yates' correction: Po0.001) ( Table 1) .
To determine whether IFN-a efficiency might depend on the step of hepatocarcinogenesis at the beginning of therapy, high-dose IFN-a therapy started after the age of 4 weeks (i.e. postinitiation of hepatocarcinogenesis, while early dysplasia was present) was compared to high-dose IFN-a therapy started at birth (i.e. prior to initiation of hepatocarcinogenesis, while early dysplasia had not appeared yet) (Figure 1 ). Our data showed that IFN-a therapy started postinitiation of hepatocarcinogenesis increased significantly the survival of X/myc mice by comparison with the nontreated controls (median: 39 vs 29 weeks; log-rank test: Po0.001), although less efficiently than IFN-a therapy started prior to initiation of hepatocarcinogenesis (median: 39 vs 58 weeks; log-rank test: P ¼ 0.01).
High-dose IFN-a therapy downregulated c-myc transgene expression and hepatocyte proliferation in the early premalignant steps
Triphasic expression of c-myc transgene was investigated by semiquantitative RT-PCR ( Figure 3 ): (1) c-myc was expressed at high level in the early premalignant steps spanning the first weeks of life, while hepatocyte dysplasia developed at 4 weeks; (2) cmyc was subsequently strongly downregulated in the late premalignant steps, while hepatocyte dysplasia was maintained in adult mice; and (3) c-myc was markedly upregulated in all HCCs (100%) arising in late dysplastic livers. Although HBV X transgene commonly mimicked cmyc expression and was found expressed at high level in many tumors, 4/16 HCCs (25%) expressed HBV X gene at low level as compared to the peritumorous liver ( Figure 4 ). These data do suggest that although HBx factor accelerates hepatocarcinogenesis as previously described in this X/myc lineage , it is likely not required for appearance and maintenance of the tumor phenotype.
To investigate the direct effect of IFN-a on c-myc and HBV X transgene expression in the early premalignant steps, 4-week-old X/myc mice were systematically killed after a 2-day-or 4-day-IFN-a therapy at high or low dose. High-dose IFN-a therapy rapidly (after a 2-day administration) and markedly repressed c-myc in early premalignant livers (at 4 weeks) as compared to nontreated transgenic controls (0.470.09 vs 1.470.38; Mann-Whitney test: Po0.01), while low-dose IFN-a therapy had only a slight impact (0.8870.26 vs 1.470.38; Mann-Whitney test: Po0.01) (Figure 3 ). Prolonged high-dose IFN-a therapy maintained low levels of c-myc transcripts in late premalignant livers, but did not prevent their increase during appearance of the tumorous phenotype at levels identical to those observed in HCCs which developed in nontreated transgenic mice (Figure 3 ). By contrast, it was observed that high-dose IFN-a therapy did not significantly reduce HBV X expression neither in premalignant steps nor in HCCs. Hepatocyte proliferation, as assessed by Figure 1 Overall survival of X/myc mice divided on the basis of IFN-a administration as measured by Kaplan-Meier analysis. The number of killed terminally ill animals (t) and the total number of mice (n) in each cohort are indicated. Diamonds, nontreated X/myc mice; triangles, mice treated from birth until being killed with lowdose IFN-a; hatched line, mice treated after the age of 4 weeks until being killed with high-dose IFN-a; squares, mice treated from birth until being killed with high-dose IFN-a Figure 2 Liver tumor histology examination of a well-differentiated HCC of the trabecular type (a) and of a microscopic HCC foci (b) (H&E Â 100)
Interferon-a and hepatocarcinogenes P Merle et al semiquantitative RT-PCR for PCNA which correlates to immunohistochemical BrdU staining of S phase hepatocytes (Merle et al., 2001) , paralleled the triphasic c-myc transgene expression in the early and late premalignant steps, as well as in HCCs ( Figure 5 ). In X/myc nontreated mice, high hepatocyte proliferation was found in early premalignant livers at 4 weeks (twofold over age-matched nontransgenic littermates; Mann-Whitney test: P ¼ 0.02) ( Figure 5 ), followed by a strong downregulation in late premalignant livers (2.3-fold lower over early premalignant livers; MannWhitney test: P ¼ 0.03). Subsequently, hepatocyte proliferation gradually increased in peritumorous dysplastic livers and HCCs (2.4-fold over corresponding peritumorous dysplastic areas; Student's t-test: Po0.0001). Interferon-a and hepatocarcinogenes P Merle et al
The proliferation index did not differ significantly between small-and large-size HCC nodules, and did not correlate with survival of animals. High-dose IFN-a therapy rapidly reduced hepatocyte proliferation (two-fold after a 4-day administration) in early premalignant livers at 4 weeks as compared to nontreated X/myc mice (Mann-Whitney test: Po0.01), while low-dose IFN-a therapy had no apparent impact ( Figure 5 ). As for c-myc, prolonged high-dose IFN-a therapy maintained low rates of hepatocyte proliferation in late premalignant livers, but did not prevent their increase during appearance of the tumorous phenotype.
High-dose IFN-a therapy did not impact on hepatocyte apoptosis
Investigation of hepatocytes undergoing cell death by the TUNEL method ( Figure 6) (Figure 7) . IFN-a therapy did not reduce mTERT mRNA levels after 2 or 4 days of therapy in early premalignant livers. Furthermore, prolonged high-dose IFN-a therapy did not impact significantly on mTERT mRNA levels in either late premalignant livers or peritumorous dysplastic areas. Noticeably, HCCs that developed under long-term IFN-a therapy conditions tended to have lower levels of mTERT mRNA than the HCCs arising in nontreated transgenics (0.6970.55 vs 0.8270.28; Mann-Whitney test: P ¼ 0.05) (Figure 7 ). All the above data correlated with semiquantitative measurement of TRAP activity (r ¼ 0.52; P ¼ 0.0007). As previous data indicated that TERT is a target of c-Myc activity (Wu et al., 1999) , we tried to identify a relation between c-myc expression and mTERT in tumors. However, no correlation was shown either in HCCs developing spontaneously (correlation Z test; P ¼ 0.38) or in HCCs developing in IFN-a-treated mice (correlation Z test: P ¼ 0.77).
Discussion
Virus-related cirrhosis are well-known etiologic factors of HCC. The poor prognosis of HCC highlights the Interferon-a and hepatocarcinogenes P Merle et al urgent need for the setting of preventive approaches, and IFN-a is the only known molecule suggesting a possible preventive effect on HCC development in clinical studies (Ikeda et al., 1998; Nishiguchi et al., 2001) . However, data from clinical trials are still controversial and no mechanisms have been clarified in these studies.
Hepatocarcinogenesis is probably multifactorial and various proto-oncogenes, tumor-suppressor genes, growth factor genes and virologic factors have been implicated (reviews in Buendia, 2000; Kondoh et al., 2001) . However, the sequence of events in the process of hepatocarcinogenesis have not been fully characterized. The proto-oncogene c-myc stimulates a pattern of cellular gene expression by its regulatory elements and is involved in gene expression during cell growth and differentiation (Evan and Littlewood, 1993) . It has been shown to be important in the process of hepatocarcinogenesis in woodchucks and transgenic mice (Hsu et al., 1988; Etiemble et al., 1994) . However, its role in human hepatocarcinogenesis remains unclear. Previous studies have shown that c-myc is barely expressed in normal liver tissue (Voravud et al., 1989) . By contrast, c-myc has been found overexpressed in most of the hepatoma cell lines and its repression by ribozyme or antisense therapy induces differentiation and growth inhibition of these cells (Farshid and Tabor, 1992; Ebinuma et al., 1999; Cheng et al., 2000) . Also, in vivo studies have shown that c-myc expression may gradually increase from normal liver to chronic hepatitis, cirrhosis and HCC (Himeno et al., 1988) . Mechanisms of c-myc overexpression during human hepatocarcinogenesis are poorly understood, but might be related to amplification of the gene or hypomethylation of its regulatory sequences (Shen et al., 1998; Kawate et al., 1999) . Speculation of c-myc overexpression as being an early event in the premalignant steps of human hepatocarcinogenesis may be of major importance since it has been found in more than 50% of human HCCs and their corresponding adjacent nontumor liver (Zhang et al., 1990; Kawate et al., 1999) . This is confirmed in several observations that have suggested that, although c-myc triggering cellular growth may play a role in the premalignant steps during the process of malignant transformation (as reflected by its high overexpression level in peritumor liver), it may not play a significant role in sustaining the growth of the tumor cells (as reflected by its lower overexpression level in the corresponding tumor tissue) (Su et al., 1985; Yuen et al., 2001) . Several studies have suggested that X gene products from mammalian Hepadnavirus might play a role in hepatocarcinogenesis. Although the exact role of the X protein remains unknown, HBx transcriptional transactivation properties have been demonstrated on a variety of viral and cellular regulatory elements. An indirect effect of HBx has been reported by activating signalling pathways mediated by the Ras-Raf-MAPK cascade or by protein kinase C in vivo and in most experimental models (Benn and Schneider, 1994) .
The X/myc transgenic mouse lineage recapitulates the different steps of experimental c-myc-induced hepatocarcinogenesis as accelerated by the HBV X viral factor . It may be a relevant experimental model for studying human hepatocarcinogenesis, since it mimicks several of the known events in humans:
(1) sequential development of hepatocyte overproliferation-dysplasia-HCC; (2) overexpression of c-myc oncogene in the early premalignant steps (Zhang et al., 1990) ; (3) frequent reactivation of insulin-growth-factor II in HCCs (Liu et al., 1997) ; (4) frequent mutations of b-catenin gene in HCCs (De La Coste et al., 1998) and (5) frequent upregulation of telomerase in HCCs (Kojima et al., 1997) .
The downregulating effect of IFN family members on c-myc has been previously described (Emat et al., 1985) . The present study in X/myc transgenic female mice showed that prolonged IFN-a therapy repressed dosedependently in vivo c-myc overexpression and hepatocyte overproliferation during the early premalignant steps, leading to a delay of microscopic HCC foci onset and subsequent increase of overall survival. The proliferation index was similar in large tumors developed in IFN-a-treated and nontreated mice. However, we ignore the impact of preventive IFN-a administration on the proliferation growth rate of the early tumors, hence the foci are smaller.
We demonstrated that prolonged IFN-a therapy was time-dependent since it was less efficient if started only after hepatocarcinogenesis initiation (as reflected by hepatocyte dysplasia onset). The threshold time was histologically identified as hepatocyte dysplasia onset at 12 weeks of age. However, further studies are needed to investigate whether a specific threshold time occurs when the IFN is no more capable of suppressing tumorigenesis. For this aim, studies on IFN-a pathway polymorphism at the different steps of hepatocarcinogenesis could focus onto the RNA-dependent protein kinase (PKR) that is likely involved in the antiproliferative and antioncogenic properties of IFN-a (Meurs et al., 1993) .
We showed that acquired resistance to IFN-a and subsequent therapeutic escape occurred lately, allowing upregulation of c-myc and hepatocyte proliferation during appearance of the tumorous phenotype. These data were in accordance with our previous findings showing in the WHV/c-myc monotransgenic mouse lineage, that early IFN-a therapy could reduce the severity of dysplastic lesions (Merle et al., 2001) . These two studies focused on IFN-a impact during premalignant steps of hepatocarcinogenesis, but not on growth inhibition or regression of established tumors as previously described in nude mice xenografted with human HCC cells , or in other immune-deficient mice allografted with murine tumor cells infected by a replication-defective adenovirus delivering IFN-b (Qin et al., 1998) .
In the present study as previously observed in the WHV/c-myc transgenic lineage, we showed that IFN-a therapy did not enhance hepatocyte apoptosis in either dysplastic or tumor livers (Merle et al., 2001) . These data do corroborate previous studies that reported the dual growth-suppressing effect of IFN-a on human liver and other cancer cell lines by inhibiting the cell-cycle progression with or without apoptosis enhancement (Chaouchi et al., 1994; Yano et al., 1999) . However, deregulation of the cell-cycle clock and apoptotic apparatus represents only a few of the changes required for malignant transformation, and acquiring immortality is another critical step (review in Lundberg and Weinberg, 1999) . The mouse telomerase is widely expressed at low levels in adult tissues and its upregulation in the vast majority of cancers indicates that this enzyme is likely linked to the process of immortalization and malignant transformation (Blasco et al., 1998) . Thus, telomerase inhibition may play a significant role in antitumor activity of IFN-a as described in hematopoietic cells (Xu et al., 2000) . In the present study, we showed that IFN-a therapy failed to reduce telomerase activity in both early and late premalignant livers, although tumors arising in high-dose IFN-a-treated mice had lower telomerase activity than HCCs arising spontaneously. Further studies are needed to determine the exact impact of IFN-a on telomerase and its contribution in repression of hepatocarcinogenesis. The results of the present study have provided some rationale to postulate that downregulation of c-myc and hepatocyte overproliferation in the early premalignant steps of hepatocarcinogenesis may be the most likely central mechanism by which IFN-a delayed hepatocarcinogenesis in X/myc mice. Indeed in the present study, the antioncogenic effect of IFN-a was neither mediated by a repression of HBV X gene which cooperates with other molecular events leading to cell transformation and proliferation (Ho¨hne et al., 1990) , nor by an immune clearance of transformed hepatocytes as reported previously (Shouval et al., 1983; Ferrantini et al., 1994) . Thus, histological examination confirmed the absence of hepatocyte necrosis induced by infiltrating immunological effector cells in both dysplastic and tumorous livers of mice treated by IFN-a (data not shown).
We can speculate that the possible antioncogenic properties of IFN-a focus mostly on the premalignant stages of hepatocarcinogenesis but have less impact upon the later stages of hepatocarcinogenesis when already multiple genetic aberrations have occurred. Further studies are therefore needed to optimize therapeutic schedules and determine the possible mechanisms of acquired resistance to IFN-a and therapeutic escape. Although a better understanding of c-myc involvement in human hepatocarcinogenesis remains necessary, our experimental model appears as a relevant tool to explore the antioncogenic properties and mode of action of INF-a in human cirrhotic livers which may be characterized by an upregulation of c-myc.
Materials and methods
Experimental animals
The 93-7 WHV/c-myc transgenic mouse model of hepatocarcinogenesis was described previously (Etiemble et al., 1994) . Transgenic mice from the AX16 lineage carrying the X open reading frame of HBV do not develop any liver tumors. The X/myc bitransgenic line, with the largely predominant C57B1/ 6 background, resulting from the crossing between 93-7 WHV/ c-myc and AX16 mice, develops HCCs significantly 2-3 months earlier than WHV/c-myc littermates (Etiemble et al., 1994; Terradillos et al., 1997) . Bitransgenic X/myc mice were identified by PCR of tail biopsy DNA with transgene-specific sets of primers covering either a fragment of the WHV genome (nucleotides 1158-1478) for WHV/c-myc transgene (Galibert et al., 1982) or a fragment of the HBV genome (nucleotides 1371-1847) for HBV X transgene (Galibert et al., 1979) . Only mice of the female gender were enrolled to remove sexdependent heterogeneity in tumor kinetics. Animals were handled and euthanized (by cervical dislocation) according to French government guidelines (Ministe`re de l'Agriculture, Services Ve´te´rinaires de la Sante´et de la Production Animale).
IFN-a treatments and grouping
Low-(5000 U/g per injection) or high-dose (25 000 U/g per injection) human recombinant IFN-a hybrid B/D (ScheringPlough Laboratories) was injected subcutaneously (s.c.) every 2 days until being killed to 71 X/myc female mice while 31 served as nontreated controls. Additional 25 age-matched C57B1/6 female mice served as nontransgenic nontreated controls.
Liver examination
Liver samples containing gross HCCs were sliced with a razor blade in order to separate HCC nodules from peritumorous areas. Histological examination showed hepatocyte dysplasia and HCC as previously described (Etiemble et al., 1994; Terradillos et al., 1997; Merle et al., 2001 ).
Detection of apoptotic hepatocytes
Sections from frozen livers were tested with the ApoAlert s DNA Fragmentation Assay Kit (Clontech Laboratories, Inc.) to detect apoptosis-induced nuclear DNA fragmentation via a fluorescent assay based on terminal deoxynucleotidyl transferase-mediated fluorescein-dUTP nick-end-labeling (TUNEL) as previously described (Merle et al., 2001) . For quantitative morphometry, 20 consecutive optic fields were counted with a conventional u.v. Leitz microscope. Apoptosis rates were expressed as the percentage of hepatocytes with stained nuclei.
RNA isolation and RT-PCR
RNA was isolated from each liver sample by Trizol (Gibco BRL, Inc.), as previously described (Merle et al., 2001) . PCR primers were as follows: (a) woodchuck c-myc, 5 0 -GAAC-CCGTGAGGTGGAAGAA-3 0 (forward) and 5 0 -TGGGTA-AAGGCGGGGAAAAG-3 0 (reverse); amplicon, 267 bp (Merle et al., 2001) ; (b) HBV X, 5 0 -TTTCCATGGCTGCTA-GGCTGT-3 0 (forward) and 5 0 -GAACAGTAGGACATGAA-CAAG-3 0 (reverse); amplicon, 477 bp (Galibert et al., 1979) ; (c) proliferating cell nuclear antigen (PCNA), 5 0 -GCTTGGCA-ATGGGAACATTA-3 0 (forward) and 5 0 -TCATCTTCAAT-CTTGGGAGC-3 0 (reverse); amplicon, 252 bp (Merle et al., 2001) ; (d) mTERT, 5 0 -CACTTTGGTTGCCCAATGCC-3 0 (forward) and 5 0 -GGCGACTACTGCTCTTGATC-3 0 (reverse); amplicon, 506 bp (Greenberg et al., 1998) and (e) GAPDH, 5 0 -CACCATCTTCCAGGAGCGAG-3 0 (forward) and 5 0 -TCACGCCACAGCTTTCCAGA-3 0 (reverse); amplicon, 372 bp (Merle et al., 2001) . The cDNAs were synthesized from total RNAs as previously described (Merle et al., 2001) , and amplified using the following PCR profile: (a) woodchuck c-myc, 941C 1 min, 621C 1 min, 721C 1 min, 30 cycles; (b) HBV X, 941C 1 min, 611C 1 min, 721C 1 min, 27 cycles; (c) PCNA, 941C 1 min, 571C 1 min, 721C 1 min, 25 cycles; (d) mTERT, 941C 1 min, 631C 1 min, 721C 1 min, 32 cycles and (e) GAPDH, 941C 1 min, 611C 1 min, 721C 1 min, 21 cycles. Under these conditions, we obtained optimization of the semiquantitative RT-PCR assays in which the amount of each RT-PCR product was directly proportional to that of the template RNA. The amplified products were separated by electrophoresis on 1.5% agarose gel and visualized after staining of the gel with Sybergreen (SYBR s Green I nucleic acid gel stain, Molecular Probes, Inc.), and their signal intensities were evaluated using an image analyzer (NIHImage version 1.58, Wayne Rasband National Institute of Health, USA). Internal control GAPDH RT-PCR was done on all samples simultaneously. Each RT-PCR was repeated three independent times using different preparations of RNA, and representative results are shown as the ratio of the intensity of each specific mRNA to that of GAPDH mRNA for each sample. The RT-PCR product specificity was confirmed at least once by Southern hybridization with a specific internal probe (Merle et al., 2001) .
Telomerase activity assay
Telomerase activity was assayed by the TRAPezet Telomerase Detection Kit (Intergen, USA), an improved version of the original PCR-based telomeric repeat amplification protocol (TRAP) (Kim et al., 1994) . Tissue extract containing 0.2 mg protein was added to 50 ml reaction mixtures and incubated at 301C for 30 min and then heat-inactivated at 941C for 3 min. PCR was performed for 31 cycles at 941C for 30 s and 591C for 30 s. PCR products were analysed by electrophoresis on a 12.5% polyacrylamide gel and visualized by direct staining of the gel with Sybergreen (SYBR s Green I nucleic acid gel stain, Molecular Probes, Inc.). Semiquantitative estimation of telomerase activity level in tissue samples was performed as previously described (Komine et al., 2000) .
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